Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

PURPOSE: To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18-IL-2) in patients with metastatic melanoma. PATIENTS AND METHODS: Thirty-three patients were treated with EMD 273063, a humanized anti-GD2 monoclonal antibody (mAb) link...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: King, David M., Albertini, Mark R., Schalch, Heidi, Hank, Jacquelyn A., Gan, Jacek, Surfus, Jean, Mahvi, David, Schiller, Joan H., Warner, Thomas, Kim, KyungMann, Eickhoff, Jens, Kendra, Kari, Reisfeld, Ralph, Gillies, Stephen D., Sondel, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: 2004
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2367368/
https://ncbi.nlm.nih.gov/pubmed/15483010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2004.11.035
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados